PMID- 36846578
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230228
IS  - 2772-7246 (Electronic)
IS  - 2772-7246 (Linking)
VI  - 4
DP  - 2022 Sep
TI  - The introduction of a novel formulation of buprenorphine into organized health 
      systems.
PG  - 100090
LID - 10.1016/j.dadr.2022.100090 [doi]
LID - 100090
AB  - BACKGROUND: Effective medications for opioid use disorder (MOUD) are 
      underutilized. This exploratory study used real-world data to analyze US 
      distribution patterns of buprenorphine extended-release (BUP-XR) within organized 
      health systems (OHS), including the Veterans Health Administration (VHA), Indian 
      Health Service (IHS), criminal justice system (CJS), and integrated delivery 
      networks (IDNs). METHODS: National BUP-XR distribution data within each OHS were 
      available from WNS Global Services and were evaluated from July 2019 through July 
      2020. BUP-XR distribution data by OHS subtype (VHA, IHS, CJS, IDN) and state were 
      aggregated and reported. RESULTS: The total distribution of BUP-XR increased from 
      6,721 units in the second half of 2019 (H2'19) to 12,925 in the first half of 
      2020 (H1'20). OHS distribution increased from H2'19 to H1'20 in every subtype but 
      was primarily driven by IDN distribution growth. IDNs accounted for 73% of total 
      units in H2'19 and continued to grow in H1'20. In H1'20, IDNs accounted for 78%, 
      VHA for 12%, CJS for 6%, and IHS for 4%. IDN distribution for BUP-XR increased 
      from 4,911 to 10,100 units, showing the highest growth rate of 106% within all 
      OHS subtypes. The states with the highest total BUP-XR distribution over the 
      12-month period were Massachusetts (4,534), Pennsylvania (3,773), and California 
      (1,866). CONCLUSIONS: Overall distribution of BUP-XR, as a treatment option for 
      OUD, is increasing; however, access to MOUD varies greatly across OHS subtypes 
      and geography. Identifying and overcoming barriers to appropriate MOUD use is 
      critical in addressing the opioid crisis.
CI  - (c) 2022 Published by Elsevier B.V.
FAU - Mullen, William
AU  - Mullen W
AD  - Indivior, Inc., Richmond, VA, USA.
FAU - Hedberg, Michaela
AU  - Hedberg M
AD  - Indivior, Inc., Richmond, VA, USA.
FAU - Gadbois, Brian
AU  - Gadbois B
AD  - BoardPrep Recovery, Tampa, FL, USA.
FAU - Heidbreder, Christian
AU  - Heidbreder C
AD  - Indivior, Inc., Richmond, VA, USA.
LA  - eng
PT  - Journal Article
DEP - 20220812
PL  - Netherlands
TA  - Drug Alcohol Depend Rep
JT  - Drug and alcohol dependence reports
JID - 9918350383506676
PMC - PMC9948815
OTO - NOTNLM
OT  - Buprenorphine, BUP-XR
OT  - Medication for opioid use disorder
OT  - Medication-assisted treatment
OT  - Opioid use disorder
COIS- Mullen, Hedberg, and Heidbreder are employees of Indivior, Inc. Gadbois is an 
      employee of the Department of Veterans Affairs and is paid by Indivior, Inc., to 
      speak about SUBLOCADE.
EDAT- 2023/02/28 06:00
MHDA- 2023/02/28 06:01
PMCR- 2022/08/12
CRDT- 2023/02/27 06:00
PHST- 2022/03/07 00:00 [received]
PHST- 2022/07/28 00:00 [revised]
PHST- 2022/07/29 00:00 [accepted]
PHST- 2023/02/27 06:00 [entrez]
PHST- 2023/02/28 06:00 [pubmed]
PHST- 2023/02/28 06:01 [medline]
PHST- 2022/08/12 00:00 [pmc-release]
AID - S2772-7246(22)00065-8 [pii]
AID - 100090 [pii]
AID - 10.1016/j.dadr.2022.100090 [doi]
PST - epublish
SO  - Drug Alcohol Depend Rep. 2022 Aug 12;4:100090. doi: 10.1016/j.dadr.2022.100090. 
      eCollection 2022 Sep.